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Gastroenterology and Hepatology, Chia-Yi Christian Hospital, Chia-Yi, TaiwanBACKGROUND & AIMS: We investigated whether 2 quantita-
tive fecal immunochemical tests (FITs) with the same cutoff
concentration of fecal hemoglobin perform equivalently in
identifying patients with colorectal cancer (CRC). METHODS: A
total of 956,005 Taiwanese subjects, 50 to 69 years old,
participated in a nationwide CRC screening program to
compare results from 2 FITs; 78% were tested using the OC-
Sensor (n ¼ 747,076; Eiken Chemical Co, Tokyo, Japan) and
22% were tested using the HM-Jack (n ¼ 208,929; Kyowa
Medex Co Ltd, Tokyo, Japan), from 2004 through 2009. The
cutoff concentration for a positive ﬁnding was 20 mg hemo-
globin/g feces, based on a standardized reporting unit system.
The tests were compared using short-term and long-term in-
dicators of performance. RESULTS: The OC-Sensor test detec-
ted CRC in 0.21% of patients, with a positive predictive value of
6.8%. The HM-Jack test detected CRC in 0.17% of patients, with
a positive predictive value of 5.2%. The rate of interval cancer
rate was 30.7/100,000 person-years among subjects receiving
the OC-Sensor test and 40.6/100,000 person-years among
those receiving the HM-Jack test; there was signiﬁcant differ-
ence in test sensitivity (80% vs 68%, P ¼ .005) that was related
to the detectability of proximal CRC. After adjusting for differ-
ences in city/county, age, sex, ambient temperature, and colo-
noscopy quality, signiﬁcant differences were observed between
the tests in the positive predictive value for cancer detection
(adjusted relative risk ¼ 1.29; 95% conﬁdence interval,
1.14–1.46) and the rates of interval cancer (0.75; 95% conﬁ-
dence interval, 0.62–0.92). Although each test was estimated to
reduce CRC mortality by approximately 10%, no signiﬁcant
difference in mortality was observed when the 2 groups were
compared. CONCLUSIONS: Different brands of quantitative
FITs, even with the same cutoff hemoglobin concentration,
perform differently in mass screening. Population-level data
should be gathered to verify the credibility of quantitative
laboratory ﬁndings.Abbreviations used in this paper: CI, conﬁdence interval; CRC, colorectal
cancer; FIT, fecal immunochemical test; ISO, International Organization
for Standardization; RR, relative risk; SR, screening rate.
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Test Sensitivity; Interval Cancer.olorectal cancer (CRC) poses a major threat to globalChealth. Because the widespread use of fecal occult-
blood tests has the potential to decrease mortality from
CRC,1 use of these tests is commonly adopted as the
preferred strategy for prevention. The traditional guaiac-
based test is being increasingly replaced by the fecal
immunochemical test (FIT), not only because the speciﬁcity
of the FIT is higher, which tends to reduce false-positive
cases, but also because the sampling method of the FIT is
more patient-friendly. In addition, because FIT ﬁndings can
be quantitated, the cutoff value for a positive test can be
adjusted to accommodate budget and manpower limitations
for a target population.2–4
In the current free-market system, different brands of
FIT may be chosen for screening, especially when an orga-
nized service screening is conducted on a nationwide scale.
However, different brands of FIT are commonly found to
have different cutoff values because FIT units are usually
expressed as the hemoglobin concentration in sampling
bottle buffers, which are not exchangeable. Interpretation of
test results has therefore become unnecessarily complex.
Difﬁculties in the interpretation of test ﬁndings are
currently faced in Taiwan, where a nationwide CRC
screening program has been in place since 2004, with
biennial FIT performed for the eligible population aged 50
to 69 years.5 The FITs most commonly used in Taiwan are
the OC-Sensor (Eiken Chemical Co, Tokyo, Japan) and the
HM-Jack (Kyowa Medex Co Ltd, Tokyo, Japan) tests, which
have cutoff concentrations of 100 and 8 ng hemoglobin/mL
buffer, respectively.
To address problems in interpretation of test ﬁndings,
an expert working group recently mandated that a
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the hemoglobin concentration in feces instead of that in the
buffer. The cutoff concentrations of the OC-Sensor and the
HM-Jack tests could therefore be transformed into 20 mg
hemoglobin/g feces.6 However, no evidence currently exists
to support the proposal that the same cutoff concentration
in feces claimed by different laboratories results in equiv-
alent performance as seen in population-based screening
programs. To test this hypothesis, both short-term and long-
term indicators of performance are needed; the former in-
cludes the positive predictive value, cancer detection rate,
interval cancer rate, and test sensitivity, and the latter is
based mainly on the CRC-speciﬁc mortality rate.7
Without a large population-based longitudinal follow-up
cohort, a thorough evaluation employing all of these in-
dicators is difﬁcult. However, a nationwide cohort composed
of nearly 1 million CRC-screened subjects recently became
available in Taiwan. This cohort was therefore utilized in the
present study to ascertain whether 2 different brands of FIT,
which claim to have identical cutoff hemoglobin concen-
trations in feces, perform equivalently for mass screening.
Both short-term and long-term indicators of performance
were measured to test this hypothesis.Methods
Screening Design
Beginning in 2004, the Taiwanese Nationwide CRC
Screening Program invited residents aged 50 to 69 years to
receive a biennial FIT.5 The main purpose of mass screening
was to reduce mortality from CRC. To cover approximately 5.5
million eligible residents in a total of 25 municipalities, the
Health Promotion Administration, Ministry of Health and Wel-
fare (formerly Bureau of Health Promotion) set the coverage
rate every 2 years for each municipality according to the
screening budget and manpower capacity. Mass screening,
including the processes of invitation, distribution of FIT, and
testing of fecal sample, the referral for colonoscopic examina-
tion, and the histopathologic diagnosis were performed in a
stepwise manner at local public health units, clinics, and hos-
pitals in each municipality, with approximately 810 screening
sites participating in the program. All screening results were
transmitted via a virtual private network to a central database
to periodically generate standardized indicators such that
central and local governments could monitor the screening
performance.Fecal Immunochemical Test Testing
The 1-day method was adopted, and participants were
advised to return the specimens for testing immediately after
they were taken. Quantitative FIT testing was performed at
approximately 125 qualiﬁed laboratories. In addition to
recording a positive or negative result, numerical data were
stored in the database for possible adjustment of the cutoff
hemoglobin concentration. Test results were reported to all
participants by mail and/or telephone. The choice of FIT was
based on the open bidding process at local Public Health Bu-
reaus and hospitals. Two major brands of FIT accounted for
approximately 82.4% of all FITs in use; these were theOC-Sensor and the HM-Jack tests with the respective cutoff
concentrations of 100 and 8 ng hemoglobin/mL buffer. The
cutoff concentrations were determined by the Health Promo-
tion Administration and based on the following calculation6:
mg hemoglobin

g feces ¼
ðnghemoglobin=mLÞðvolumeof thedevice buffer inmLÞ
ðmass of feces collected inmgÞ
Because the mass of feces collected and volume of the de-
vice buffer were claimed as 10 mg and 2 mL, respectively, for
OC-Sensor and 0.5 mg and 1.25 mL, respectively, for HM-Jack,
the cutoff hemoglobin concentrations in buffer for both tests
were equivalent to 20 mg hemoglobin/g feces.
To monitor quality control within individual laboratories,
the Health Promotion Administration has authorized the
Taiwan Society of Laboratory Medicine to provide these labo-
ratories with hemoglobin solutions and hemoglobin-spiked,
stool-like matrix samples to test occult blood using both FITs
every 6 months. Participating laboratories were required to
analyze these test materials and return the ﬁndings for evalu-
ation. Only accredited laboratories with ﬁndings that met the
requirements of the International Organization for Standardi-
zation 15189 could participate in the nationwide program.
Conﬁrmatory Diagnosis
A participant with a positive test was referred to one of
approximately 485 hospitals for the conﬁrmatory diagnosis
with either a total colonoscopy or sigmoidoscopy plus barium
enema. Details regarding size, location, and histopathology for
colonic neoplasms were recorded. The histopathology of a
colorectal neoplasm was classiﬁed according to the criteria of
the World Health Organization.8
Performance Indicators of Fecal
Immunochemical Test
Test performance was evaluated based on data from the
prevalence screening. Short-term indicators included positive
predictive value for cancer detection (number with cancer/to-
tal number of diagnostic endoscopies) and cancer detection
rate (number with cancer/tested population). The detection of
advanced adenoma, which was deﬁned as an adenoma of 10
mm in diameter or having a villous component or high-grade
dysplasia, was included in the calculations for the above in-
dicators. The per-person analysis was used for both the CRC (ie,
an individual discovered with metachronous cancers counted
as one individual with cancer) and advanced adenoma (ie, the
most advanced ﬁnding being an advanced adenoma). Short-
term indicators also included the interval cancer rate (num-
ber of invasive cancers diagnosed after a negative FIT and <2
years to the next screen/total person-years at risk). To ascer-
tain the occurrence of incident CRC, the screening database was
linked with the Taiwan Cancer Registry, a nationwide program
with high coverage (99%; each hospital mandated to report
all cases of CRC) and high accuracy (percentage of death-
certiﬁcate–only cases of <1% for CRC).9 The indicator of test
sensitivity was generated from the number of interval cancers
using the proportional incidence method based on age- and sex-
speciﬁc incidence rates derived from the Taiwan Cancer Reg-
istry. Adjustments were also made for the variation of sojourn
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phase.10,11 The following equation was used:
Sensitivity ¼ 1 IT=I
1 1T
Z T
0
F

t

dt
where IT is the incidence of interval cancer in time T after the
ﬁrst screening, I is the baseline incidence in the absence of
screening, and F(t) is the probability distribution function of
the preclinical detectable phase. The calculation is detailed in
Supplementary Table 1.
As the number of eligible population was large, the phase-in
approach was used by the nationwide screening program for
gradual expansion of the coverage rate year by year. Person-years
for each individual were calculated from the date of entry to the
end of follow-up, which was deﬁned as the earlier of the occur-
rence of an event or the end of the study in December 31, 2009.Statistical Analysis
Differences in baseline characteristics between the 2
screened populations were determined by applying the Student
t or c2 test. For the univariate analyses of test performance, the
2- sample proportion test was used to compare the 2 FITs with
respect to the positive rate, referral rate for conﬁrmatory
diagnosis, positive predictive value, and cancer and advanced
adenoma detection rates. For the comparisons of interval can-
cer rate and test sensitivity, the Poisson method was used.
Because advanced age and male sex are known to be risk fac-
tors for colorectal neoplasms,12 results stratiﬁed according to
these 2 factors are also reported.
It was considered essential to validate the results of FIT
performance by adjusting for inﬂuences other than brand of FIT,
such as age, sex, referral rate for conﬁrmatory endoscopy, city/
county, ambient temperature during sampling, transport and
storage before analysis, and the quality of colonoscopy (for pos-
itive predictive value and detection rate), each of which could
lead to a difference in the detection of CRC between the 2
screened populations. To this end, a multivariable Poisson
regression model with the outcome variables of positive predic-
tive values for advanced adenomadetection and cancer detection,
advanced adenoma and cancer detection rates, and interval
cancer rate, respectively, was applied with results expressed as
the adjusted relative risk (RR) and the corresponding 95% con-
ﬁdence interval (CI). Average monthly ambient temperature data
were obtained from the Central Weather Bureau.
For the long-term indicator of CRC mortality, the screening
database was linked with the National Mortality Registry of
Taiwan to ascertain CRC-speciﬁc death during the period of
2004–2009 in order to calculate the CRC-speciﬁc mortality rate
(number of deaths attributed to the colorectal cancer/total
person-years at risk) for both FITs. The death certiﬁcate in
Taiwan was issued by the physician in charge who judged the
disease or condition directly responsible for the death and
recorded this information; the certiﬁcate was reviewed and
coded at the central government according to the ICD-9. The
major error rate (ie, incorrect causal sequence reported or only
mechanism of death reported)was approximately 9%.13 The Cox
proportional hazards model was used to estimate the relativemortality between the 2 tests by taking into account the differ-
ences in CRC-speciﬁc death and follow-up time between the 2
screened populations, right censoring at the last day of follow-
up, or the competing cause of death. The results were
expressed as hazard ratios and the corresponding 95% CIs.
In addition to the relative mortality between the 2 FITs, the
absolute mortality reduction for each FIT was estimated and
compared with nonparticipants with the adjustment of self-
selection bias.14 The following equation was applied:
RRadjusted for self-selection bias¼ Screeningrate ðSRÞ
 RRparticipants=uninvitedþð1SRÞ
 RRnon-participants=uninvited
The calculation is detailed in Supplementary Tables 2–4.
Because the stage and location of screen-detected and in-
terval cancers are of clinical signiﬁcance,15 a subsidiary anal-
ysis was performed and a comparison was made between the 2
tests using the c2 test. Cancer was staged according to the
American Joint Committee on Cancer 7th staging system.16 The
colon above the level of the splenic ﬂexure (including the
splenic ﬂexure) was deﬁned as the proximal colon. When
concurrent proximal and distal cancers were present, subjects
were placed into the distal colon category. All statistical ana-
lyses were performed using SAS version 9.2 (SAS Institute,
Cary, NC). All P values were 2-sided and P < .05 was considered
to indicate statistical signiﬁcance.Results
Baseline Characteristics
Between January 1, 2004 and December 31, 2009, a total
of 956,005 subjects underwent screening. Among them,
747,076 (78%) and 208,929 (22%) received the OC-Sensor
and HM-Jack tests, respectively; their baseline data accord-
ing to demographic characteristics, geography, and temper-
ature, and characteristics of the conﬁrmatory diagnosis are
presented in Table 1. Small differences, which were statisti-
cally signiﬁcant owing to the large sample size, were
observed with respect to sex, follow-up time, conﬁrmatory
examination tool, colonoscopy adenoma detection rate, and
colonoscopy advanced adenoma detection rate. Differences
were more prominent in the geographic areas and the hos-
pital levels where conﬁrmatory diagnoses were performed.
Positivity Rate and Referral Rate
As shown in Table 2, positivity rates were similar be-
tween the 2 tests (3.8% vs 3.9%), but the conﬁrmatory
examination rate was higher for those who received HM-
Jack (80.9% vs 85.3%). As expected, positivity rates were
higher for males and those of older age as compared with
the total population group. These ﬁndings were unchanged
regardless of adjustments for sex and age distributions
(data not shown).
The effect of ambient temperature on FIT positivity was
also evaluated. For the temperature ranges of 10–14C,
15–19C, 20–24C, and 25C, the positivity rates for OC-
Sensor were 5.6%, 4.4%, 3.9%, and 3.6%, respectively,
Table 1.Baseline Characteristics of the Screened Population
Characteristics FIT 1a (n ¼ 747,076) FIT 2b (n ¼ 208,929) P value
Demographic characteristics
Age, years, mean ± SD 58.42 ± 5.80 57.89 ± 5.76 .95
Sex, n (%)
Male 286,408 (38.3) 80,821 (38.7) .004
Female 460,668 (61.7) 128,108 (61.3)
Follow-up time with the end point of mortality, y, mean ± SD 3.17 ± 1.55 3.00 ± 1.26 <.001
Geography and temperature
Geographic area, n (%)
Northern area 392,119 (52.5) 40,631 (19.4) <.001
Central area 107,537 (14.4) 105,456 (50.5)
Southern area 207,929 (27.8) 49,509 (23.7)
Eastern area and offshore island 39,491 (5.3) 13,333 (6.4)
Ambient temperature, C, mean ± SD
Overall 26.05 ± 3.19 26.06 ± 3.08 .99
Spring 21.86 ± 2.55 22.20 ± 2.08 .92
Summer 27.52 ± 1.82 27.31 ± 1.94 .94
Autumn 27.47 ± 1.72 27.73 ± 1.52 .91
Winter 21.72 ± 2.64 20.13 ± 2.47 .66
Conﬁrmatory examination characteristics
Time to conﬁrmatory examination, months, mean ± SD 1.18 ± 1.79 1.02 ± 1.41 .94
Hospital level for conﬁrmatory diagnosis, n (%) <.001
Medical center 5958 (26.2) 1194 (17.2)
Regional hospital 9792 (43.1) 3569 (51.6)
Local hospital and clinic 5787 (25.4) 1888 (27.3)
Nonspeciﬁed 1199 (5.3) 272 (3.9)
Conﬁrmatory examination tool, n (%) <.001
Colonoscopy 19,599 (86.2) 6178 (89.2)
Sigmoidoscopy ± barium enema 3063 (13.5) 744 (10.8)
Missing data 74 (0.3) 1 (0.0)
Screened-detected cancer, n (per 1000) 1546 (2.1) 359 (1.7) <.001
Colonoscopic quality indicator (%)
Cecal intubation ratec 79.8 79.6 .76
Adenoma detection rated 45.6 43.0 <.001
Advanced adenoma detection rated 15.0 12.7 <.001
Resection rate of <2 cm adenomae 83.5 80.0 .61
aFIT 1 ¼ OC-Sensor.
bFIT 2 ¼ HM-Jack.
cCecal intubation rate was deﬁned as the number of subjects with cecal intubation/the number of subjects screened with
colonoscopy.
d(Advanced) adenoma detection rate was deﬁned as the number of subjects with at least one detected (advanced) adenoma/
the number of subjects positive to FIT having attended a colonoscopy.
eResection rate of <2 cm adenoma was deﬁned as the number of subjects with resection of adenoma/the number of subjects
with at least one detected <2 cm adenoma having attended a colonoscopy.
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respectively, revealing an inverse association (P < .001)
between FIT positivity and ambient temperature.
Positive Predictive Value and Detection Rate
The OC-Sensor test detected CRC in 0.21% of patients,
with a positive predictive value of 6.8%. The HM-Jack test
detected CRC in 0.17% of patients, with a positive predictive
value of 5.2%. The positive predictive value and the cancer
detection rate were signiﬁcantly higher with OC-Sensor than
with HM-Jack (Table 3). Positive predictive values and
cancer detection rates were also higher for male sex and
older age groups as compared with the total population
group. When advanced adenoma was used as the index
lesion, a higher positive predictive value was seen withOC-Sensor as compared with HM-Jack, but advanced ade-
noma detection rates were similar between the 2 tests.
Interval Cancer Rate and Test Sensitivity
As shown in Table 4, the interval cancer rate for OC-
Sensor was lower than that for HM-Jack (30.7 vs 40.6 per
100,000 person-years), resulting in a signiﬁcant difference
in test sensitivities (80% vs 68%; P ¼ .005). The test
sensitivity for each FIT was, however, similar among
different subgroups stratiﬁed according to sex and age.
To consider adherence to the screening process, the 2-
year sensitivity of the screening program was evaluated by
including into the calculation of interval cancers those in-
dividuals who had positive FIT ﬁndings, followed by a
negative assessment or no additional assessment.17 Using
Table 2.Numbers of Tested Population, Positive Tests, and Conﬁrmatory Diagnoses Stratiﬁed by the Age, Sex, and Brands of
Quantitative Fecal Immunochemical Tests
Brands of FIT
Tested population Positive test Positivity rate, %
Diagnostic
examination
Referral rate for diagnostic
examination, %
FIT 1a FIT 2b FIT 1 FIT 2 FIT 1 FIT 2 FIT 1 FIT 2 FIT 1 FIT 2
Male
50–59 years 169,711 48,645 6876 1866 4.1c 3.8c 5605 1575 81.5c 84.4c
60–69 years 116,697 32,176 6834 1927 5.9 6.0 5528 1639 80.9d 85.1d
Subtotal 286,408 80,821 13,710 3793 4.7 4.7 11,133 3214 81.2d 84.7d
Female
50–59 years 302,278 85,471 8380 2555 2.8d 3.0d 6823 2192 81.4d 85.8d
60–69 years 158,390 42,637 6016 1773 3.8d 4.2d 4780 1517 79.5d 85.6d
Subtotal 460,668 128,108 14,396 4328 3.1d 3.4d 11,603 3709 80.6d 85.7d
Both sexes
50–59 years 471,989 134,116 15,256 4421 3.2 3.3 12,428 3767 81.5d 85.2d
60–69 years 275,087 74,813 12,850 3700 4.7d 5.0d 10,308 3156 80.2d 85.3d
Total 747,076 208,929 28,106 8121 3.8 3.9 22,736 6923 80.9d 85.3d
aFIT 1, OC-Sensor.
bFIT 2, HM-Jack.
cP < .05 or dP < .01 in the comparison between FIT 1 and FIT 2.
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between the 2 FITs (OC-Sensor: 77%; 95% CI, 73%–81% vs
HM-Jack: 67%; 95% CI, 60%–75%; P ¼ .027).Multivariate Analyses
Taking into account the differences in baseline charac-
teristics of the 2 screened populations, multivariate analyses
with the adjustments of demographics, geography, and tem-
perature, and hospital levels (an indicator for the quality of
conﬁrmatory diagnosis as shown in Supplementary Table 5)
were performed. As shown in Table 5, ﬁndings were
remarkably similar to those obtained from the univariateTable 3.Positive Predictive Values and Detection Rates for the
Age, Sex, and the Brands of Quantitative Fecal Immun
Brands of FIT
Positive predictive value, %
Advanced adenoma Colorectal can
FIT 1a FIT 2b FIT 1 F
Male
50–59 years 17.1 15.8 5.9
60–69 years 17.5 16.3 9.4 c
Subtotal 17.3 16.1 7.6d
Female
50–59 years 8.7c 6.7 c 5.3 c
60–69 years 10.0 9.3 7.1 c
Subtotal 9.2c 7.7 c 6.0d
Both sexes
50–59 years 12.5d 10.5d 5.5c
60–69 years 14.0 12.9 8.3d
Total 13.2d 11.6d 6.8d
aFIT 1, OC-Sensor.
bFIT 2, HM-Jack.
cP < .05 or dP < .01 in the comparison between FIT 1 and FITanalyses: a higher positive predictive value for cancer
detection and a lower interval cancer rate were noted for OC-
Sensor as compared with HM-Jack, with the exception that no
signiﬁcant difference in the cancer detection rate was
observed. With respect to detection of advanced adenoma,
the positive predictive value remained higher for OC-Sensor
as compared with HM-Jack, but the advanced adenoma
detection rate was similar for the 2 tests.Colorectal Cancer Mortality
Regarding relative mortality rates between the 2
screened populations, the crude and adjusted (for age andAdvanced Adenoma and Colorectal Cancer According to the
ochemical Tests
Detection rate (per 1000)
cer Advanced adenoma Colorectal cancer
IT 2 FIT 1 FIT 2 FIT 1 FIT 2
4.8 5.6 5.1 1.9 1.5
7.0c 8.3 8.3 4.4 3.6
5.9d 6.7 6.4 3.0d 2.4d
4.1c 2.0 1.7 1.2 1.0
5.3c 3.0 3.3 2.2 1.9
4.6d 2.3 2.2 1.5 1.3
4.4c 3.3 3.0 1.5 1.2
6.2d 5.3 5.5 3.1c 2.6c
5.2d 4.0 3.8 2.1d 1.7d
2.
Table 4.Comparisons of the Number of Interval Cancer, Interval Cancer Rate, and Test Sensitivity Between 2 Quantitative
Fecal Immunochemical Tests
Person-year
at riska No. of ICs
Incidence of IC (expected
incidence in the absence
of screening)b
Proportional
incidence
1-proportional
incidence, % (95% CI)
Test sensitivity,
% (95% CI)c
FIT 1d
Male
50–59 years 328,335 85 25.9 (72.9) 0.36 64 (57–73) 75 (66–85)
60–69 years 235,674 141 59.8 (177.5) 0.34 66 (60–73) 79 (71–86)
Subtotal 564,009 226 40.1 (116.6) 0.34 66 (61–71) 77 (71–83)
Female
50–59 years 607,842 97 16.0 (53.1) 0.30 70 (63–78) 82 (74–92)
60–69 years 328,778 137 41.7 (129.4) 0.32 68 (62–75) 79 (72–87)
Subtotal 936,620 234 25.0 (79.9) 0.31 69 (64–74) 80 (75–86)
Both sexes
50–59 years 936,177 182 19.4 (62.9) 0.31 69 (64–75) 81 (74–88)
60–69 years 564,452 278 49.3 (152.6) 0.32 68 (63–72) 80 (74–85)
Total 1,500,629 460 30.7 (96.6) 0.32 68 (65–72) 80 (76–84)e
FIT 2f
Male
50–59 years 69,740 23 33.0 (72.9) 0.45 55 (42–72) 64 (49–84)
60–69 years 50,054 37 73.9 (177.5) 0.42 58 (47–72) 69 (56–84)
Subtotal 119,794 60 50.1 (116.6) 0.43 57 (48–67) 67 (57–79)
Female
50–59 years 127,145 32 25.2 (53.1) 0.47 53 (41–67) 62 (48–78)
60–69 years 68,482 36 52.6 (129.4) 0.41 59 (48–73) 71 (58–87)
Subtotal 195,627 68 34.8 (79.8) 0.44 56 (48–66) 67 (57–78)
Both sexes
50–59 years 196,885 55 27.9 (62.9) 0.44 56 (47–66) 65 (55–78)
60–69 years 118,536 73 61.6 (152.6) 0.40 60 (52–69) 71 (61–82)
Total 315,421 128 40.6 (96.6) 0.42 58 (52–65) 68 (61–76)e
IC, interval cancer.
aThe interval cancer was deﬁned as a cancer that developed in the interval of 2 years after a negative FIT result. For those who
had >2 years of follow-up but did not receive the subsequent screening, their follow-up time was set at 2 years in the
calculation of person-years at risk.
bPer 100,000 person-years.
cThe test sensitivity was adjusted for sojourn time when colorectal cancer was in the preclinical detectable phase; the
calculation is detailed in Supplementary Table 1.
dFIT 1, OC-Sensor.
eP < .01 in the comparison between FIT 1 and FIT 2.
fFIT 2, HM-Jack.
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0.91–1.61) and 1.22 (95% CI, 0.92–1.63), respectively, when
OC-Sensor was compared with HM-Jack; the difference be-
tween the 2 groups was not signiﬁcant. Regarding the abso-
lute mortality reduction with the adjustment of self-selection
bias, the results were 11% (95% CI, 6%–16%) and 13%
(95% CI, 7%–18%), respectively, for the OC-Sensor and HM-
Jack, as compared with nonparticipants, given the screening
rate of 21.4% during the study period; the difference be-
tween the 2 FITs remained nonsigniﬁcant (P ¼ .20).Stage and Location of Screen-Detected Cancer
and Interval Cancer
Findings are presented in Table 6. Regarding the cancer
stage for the overall population, the proportions of stage
0–I CRC were 21.1%, 47.3%, and 35.5% for non–screen-
detected cancer, screen-detected cancer, and intervalcancer, respectively. Regarding the 2 FITs, stage 0–I CRC
accounted for 47.5% and 46.1% of screen-detected cancers
for OC-Sensor and HM-Jack, respectively; this difference was
not signiﬁcant (P ¼ .67). With regard to interval cancer, no
signiﬁcant differences (P ¼ .62) in the distributions of
cancer stage were observed between the 2 tests. For both
tests, the test sensitivities for stage 0–I and stage II–IV CRCs
were estimated to be 62% (95% CI, 60%–64%) and 91%
(95% CI, 90%–92%), respectively.
Regarding the location of CRC in the overall population,
the proportions of proximally located CRC were 23.4%,
27.2%, and 23.8% for non–screen-detected cancer, screen-
detected cancer, and interval cancer, respectively.
Regarding the 2 FITs and the location of screen-detected
cancer, a slightly higher percentage of proximally located
CRC was observed for OC-Sensor as compared with HM-Jack
(28.1% vs 23.4%; P ¼ .06). Concerning the 2 FITs and the
location of interval cancer, a signiﬁcantly higher percentage
Table 6.Comparisons of Cancer Stage and Location
Between 2 Quantitative Fecal Immunochemical
Tests
Screen-detected
cancer, n (%)
Interval
cancer, n (%)
Cancer stage
FIT 1a
0 146 (12.2) 39 (10.2)
I 423 (35.3) 101 (26.5)
II 262 (21.9) 71 (18.6)
III 278 (23.2) 107 (28.1)
IV 88 (7.4) 63 (16.6)
Total 1197 (100) 381 (100)
FIT 2b
0 38 (13.4) 10 (9.9)
I 93 (32.7) 21 (20.8)
II 73 (25.7) 20 (19.8)
III 61 (21.5) 35 (34.7)
IV 19 (6.7) 15 (14.8)
Total 284 (100) 101 (100)
Cancer location
FIT 1
Proximal colon 435 (28.1) 100 (22.0)
Distal colon 1111 (71.9) 355 (78.0)
Total 1546 (100) 455 (100)
FIT 2
Proximal colon 84 (23.4) 35 (31.0)
Distal colon 275 (76.6) 78 (69.0)
Total 359 (100) 113 (100)
NOTE. In the FIT 1, 349 and 79 cases did not have the in-
formation of cancer stages of the screen-detected and in-
terval cancers, respectively, and in the FIT 2, the respective
numbers were 75 and 27. Regarding the cancer location, 5
and 15 interval cancer cases did not have information for the
FIT 1 and FIT 2, respectively.
aFIT 1, OC-Sensor.
bFIT 2, HM-Jack.
Table 5.Comparisons of the Test Performance Between 2
Quantitative Fecal Immunochemical Tests Using the
Poisson Regression Models
Model Relative risk 95% CI
Positive predictive value for advanced
adenoma detection
Model 1a
FITb 1 vs FIT 2c 1.14 1.05–1.23d
Model 2e
FIT 1 vs FIT 2 1.13 1.03–1.24d
Age 60–69 vs 50–59 years 1.09 1.02–1.17d
Male vs female 1.91 1.79–2.04d
Mean ambient temperature,C 1.00 0.99–1.01
Medical center/regional hospital vs
local hospital/clinic
1.00 0.91–1.11
Advanced adenoma detection rate
Model 1
FIT 1 vs FIT 2 1.06 0.98–1.15
Model 2
FIT 1 vs FIT 2 0.99 0.85–1.15
Age 60–69 vs 50–59 years 1.07 0.96–1.19
Male vs female 2.04 1.84–2.27d
Mean ambient temperature,C 0.99 0.97–1.00
Medical center/regional hospital vs
local hospital/clinic
0.93 0.81–1.08
Positive predictive value for cancer
detection
Model 1
FIT 1 vs FIT 2 1.30 1.15–1.46d
Model 2
FIT 1 vs FIT 2 1.29 1.14–1.46d
Age 60–69 vs 50–59 years 1.45 1.31–1.60d
Male vs female 1.24 1.14–1.35d
Mean ambient temperature,C 1.02 1.00–1.03d
Medical center/regional hospital vs
local hospital/clinic
1.40 1.26–1.55d
Cancer detection rate
Model 1
FIT 1 vs FIT 2 1.20 1.07–1.35d
Model 2
FIT 1 vs FIT 2 1.02 0.84–1.24
Age 60–69 vs 50–59 years 1.44 1.26–1.66d
Male vs female 1.51 1.34–1.69d
Mean ambient temperature,C 1.00 0.98–1.02
Medical center/regional hospital vs
local hospital/clinic
1.32 1.12–1.56d
Table 5.Continued
Model Relative risk 95% CI
Interval cancer rate
Model 1
FIT 1 vs FIT 2 0.76 0.62–0.92d
Model 2
FIT 1 vs FIT 2 0.75 0.62–0.92d
Age 60–69 vs 50–59 years 2.39 2.02–2.81d
Male vs female 1.47 1.25–1.73d
Mean ambient temperature,C 1.00 0.97–1.03
aModel 1: the crude Poisson regression model; model 2: the
multivariate Poisson regression model adjusted for the city/
county clustering, age, and sex distributions, the monthly
mean ambient temperature (a quantitative variable) for the
positive predictive value and detection rate.
bFIT 1, OC-Sensor.
cFIT 2, HM-Jack.
dP < .05.
eModel 2: the multivariate Poisson regression model adjusted
for the hospital levels (a dichotomous predictor to represent
the colonoscopy quality) for the positive predictive value and
detection rate.
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Jack as compared with OC-Sensor (31% vs 22%; P ¼ .044).
Additionally, test sensitivities were estimated according
to proximal and distal CRC. For OC-Sensor, the test sensi-
tivities were 81% (95% CI, 72%–90%) and 81% (95% CI,
76%–85%) for proximal and distal CRC, respectively
(P ¼ .99), and for HM-Jack, the test sensitivities were 56%
(95% CI, 44%–71%) and 79% (95% CI, 70%–90%),
respectively (P ¼ .006). When the 2 FITs were compared, a
signiﬁcant difference in the test sensitivity between the 2
tests was observed for proximal cancer (P ¼ .003), but not
for distal cancer (P ¼ .69).
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In the present study, a single quantitative threshold for
FIT, even when calculated as the mass of feces collected in
relation to the buffer volume, was not found to function
identically across products for detection of CRC. In addition,
the speciﬁc epitopes of hemoglobin detected by different
tests are likely to have contributed substantially to test
performance. Although important differences in short-term
indicators were identiﬁed, no signiﬁcant difference in sub-
sequent CRC mortality was observed between the 2 quan-
titative FITs mostly commonly used in Taiwan.
Features and ﬁndings of population-based screening
studies based on quantitative FITs are summarized in
Supplementary Table 6.18–31 Among different brands of FIT,
manufacturer cutoff concentrations range from 8 to 176 ng
hemoglobin/mL buffer; however, after transformation to the
proposed standardized unit, this range narrows to 15–67 mg
hemoglobin/g feces. This transformation supports, in part,
the use of the proposed standardized unit because the cutoff
concentration of FITs is usually designed to ﬁt the screening
capacity of endoscopists, a capacity that is globally con-
strained. Based on OC-Sensor with the cutoff concentration of
20 mg hemoglobin/g feces, the reported positive rate, positive
predictive value for cancer detection, and cancer detection
rate have been found to range from 3.8% to 6.1%, from 5.8%
to 10.2%, and from 2.1% to 3.3%, respectively. Such varia-
tions may reﬂect the observation that, without a randomized
allocation, performance indicators are affected by differences
in baseline characteristics.32,33 Nonetheless, the advantage of
a quantitative FIT can be found by comparing the ﬁndings of
Faivre et al26 with those of Quintero et al28; adjustment of the
cutoff concentration from 30 to 15 mg hemoglobin/g feces
yielded a higher positive rate but a lower positive predictive
value. Regarding different FITs with different manufacturer
cutoff concentrations, comparisons would prove difﬁcult in
the absence of an experimental design and sophisticated
analysis.27
In the present study, test sensitivity was established to
be the most objective indicator for comparison as this in-
dicator is much less affected by the age and sex of the
screened population. In a study involving Italian subjects,
test sensitivities ranging from 73.2% to 82.1% were re-
ported using different generations of FITs from the same
manufacturer (OC-Hemodia or OC-Sensor-micro) with the
same cutoff concentration (20 mg hemoglobin/g feces).19–21
In the present study, in which the cutoff concentration was
also 20 mg hemoglobin/g feces, a substantial difference in
test sensitivities (68% vs 80%) was observed between FITs
from 2 different manufacturers. This difference became
especially apparent in the present study because a nation-
wide cohort composed of nearly 1 million CRC-screened
subjects was utilized.
In the present study, the positive predictive value for
either advanced adenoma or CRC differed between the 2
FITs regardless of the similar test positivity rates. This
ﬁnding indicated that some analytical factor other than the
mass of feces and volume of buffer may have affected the
transferability between different FITs. Both FITs apply theturbidimetric immunoassay based on anti-human hemo-
globin polyclonal antibodies, and manufacturers provide
users with validated calibrators and reagents. These anti-
bodies may display 100% reactivity with intact hemoglobin
(calibrator); however, heterogeneous forms of hemoglobin
are found in stools; both intact and partially denatured
forms are observed. The degree to which available anti-
bodies react with denatured hemoglobin has not been
established. Furthermore, immunized antibodies may cross-
react to some extent with human protein contaminants, with
each manufacturer providing its own procedure for
absorbing the nonspeciﬁc antibodies reacting with these
contaminants. It therefore appears reasonable to speculate
that, because they employ different antibodies, the 2 FITs
examined in the present study detect different spectra of
hemoglobin breakdown products. In addition, the different
capacities of these FITs to detect partially degraded globin
moieties are likely to result in different sensitivities for
proximal CRC, where degradation of hemoglobin exceeds
that of distal cancers.34 This speculation is supported by the
ﬁndings35–37 that reduced sensitivity of FITs for proximal
colon lesions is related to hemoglobin breakdown during
transit with loss of detectable epitopes.
Undoubtedly, the transferability of quantitative results
between different FITs can be improved through use of a
standardized reporting unit system; however, ﬁndings of the
present study reveal that current systems are not adequate
for this purpose. In particular, antibodies provided by man-
ufacturers of FITs are likely to differ considerably. To
address this problem, theWorld Endoscopy Organization has
proposed that an independent calibration process of
analytical performance is needed, in which the system under
investigation is compared with an internationally accepted
hemoglobin standard (eg, artiﬁcial stool material).38,39
Findings of the present report support this proposal.
Strengths of the present study include the large sample
size, long follow-up time, execution on a nationwide scale,
and registry of cancer incidence and mortality, such that
both short-term and long-term indicators could be evalu-
ated. In addition to highlighting the need to improve the
capacity of FITs to detect proximal CRC, ﬁndings of the
present study support the ﬁndings of others40 that hemo-
globin concentrations fall at higher ambient temperatures;
the latter indicates the need to improve the stability of he-
moglobin molecules present in fecal samples before con-
ducting measurements. However, certain limitations of the
present study should be noted. First, this study was not a
randomized trial; the higher adherence rate of subjects
receiving HM-Jack for diagnostic examination may have
attenuated the differences in the advanced adenoma
detection rate and cancer detection rate between this group
and those receiving OC-Sensor. In addition, their shorter
follow-up time, which was related to the later marketing
and selling of HM-Jack in Taiwan, may have led to an un-
derestimation of the difference in test sensitivity between
the 2 FITs. Although regression analysis was employed in an
attempt to address the baseline difference between the 2
groups, the absolute differences in test performance were
small and residual confounding from measured or
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quantitative nature of this study, the possibility that some
laboratories have adjusted the cutoff concentrations for
both tests according to local screening capacities cannot be
excluded. However, results in the conventional ranges of
50–100 ng hemoglobin/mL buffer for OC-Sensor and 8–12
ng hemoglobin/mL buffer for HM-Jack accounted for only
3% of both measures in the present study, and almost all
interval cancers were below the deﬁned cutoff concentra-
tions and unlikely to alter the ﬁndings. Third, during this
extended study period, the manufacturers may have modi-
ﬁed the composition of test reagents without informing
users of the potential effects of such modiﬁcations on
analytical performance.39 Additionally, the ﬁndings of this
report may not apply to updated products (eg, HM-Jackarc,
launched in 2011 with different system, collection device,
and analytical range). In a recent Italian study inviting
subjects to receive both HM-Jack and OC-Sensor tests,41 the
same cutoff concentration of HM-Jack was associated with a
higher test positivity rate than that associated with OC-
Sensor (6.2% vs 3.5%). This observation is consistent with
the ﬁndings of the present study that, even though a stan-
dardized reporting unit system was selected, identical he-
moglobin thresholds performed differently between
products and product performance depended on the speciﬁc
mechanics of the test. Finally, although both FITs were
found to be associated with reduced CRC mortality, the
signiﬁcant difference in test sensitivities observed between
them should theoretically have been associated with
different CRC mortalities. However, no difference in CRC
mortality was observed. Because both tests were able to
detect signiﬁcant proportions (approximately 50%) of
early-stage CRC and because the prognosis for advanced
cancer is improved by advances in cancer treatment, it is
conceivable that the follow-up time may not have been
adequate for evaluation of this indicator; additional obser-
vation is needed.
In conclusion, a discrepancy in FIT performance be-
tween laboratory and population levels was observed.
Different brands of FIT, which claimed the same cutoff
concentration of hemoglobin in feces, performed differently
in mass screening. In addition to the measurements of fecal
mass collected/volume of buffer in the collection bottle, the
capacities of different antibodies to detect different epitopes
of degraded hemoglobin may decrease the transferability of
the standardized reporting unit system. A transparent
veriﬁcation of the quantitative ﬁndings from use of existing
FITs is therefore anticipated. For an ongoing mass screening
program, the present study lends support to continued ef-
forts to monitor test sensitivity in order to improve the
effectiveness of FIT screening and thereby decrease the
occurrence of interval cancer.
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